Follicle-stimulating hormone(FSH)levels prior to prostatectomy are not related to long-term oncologic or cardiovascular outcomes for men with prostate cancer

作     者：Kassim Kourbanhoussen France-Hélène Joncas Christopher JD Wallis Hélène Hovington Francois Dagenais Yves Fradet Chantal Guillemette Louis Lacombe Paul Toren Kassim Kourbanhoussen;France-Hélène Joncas;Christopher JD Wallis;Hélène Hovington;Fran?ois Dagenais;Yves Fradet;Chantal Guillemette;Louis Lacombe;Paul Toren

作者机构：Department of SurgeryFaculty of MedicineUniversitéLavalCHU de Québec Research CenterOncology DivisionQuebec City G1R3S1Canada Department of UrologyVanderbilt University Medical CenterNashvilleTN 37232USA Institut Universitaire Cardiologie et Pneumologie de QuébecQuebec City G1V 4G5Canada Faculty of PharmacyUniversitéLavalCHU de Québec Research CenterQuebec City G1V 4G2Canada 

出 版 物：《Asian Journal of Andrology》 (亚洲男性学杂志（英文版）)

年 卷 期：2022年第24卷第1期

页      面：21-25页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：Funding support was provided by a clinician–scientist award from Fonds de Recherche du Quebec–Sante(#32774) a Prostate Cancer Canada Movember Discovery Grant(D2016-1393) 

主　　题：cardiovascular events follicle-stimulating hormone prostate cancer recurrence 

摘      要：Prior research suggests a link between circulating levels of follicle-stimulating hormone(FSH)and prostate cancer *** levels may also explain some of the observed differences in cardiovascular events among men treated with gonadotropin-releasing hormone(GnRH)antagonists compared to GnRH *** study evaluates the association between preoperative FSH and long-term cardiovascular and oncologic outcomes in a cohort of men with long follow-up after radical *** performed a cohort study utilizing an institutional biobank with annotated clinical *** levels were measured from cryopreserved plasma and compared with sex steroids previously measured from the same *** in oncologic outcomes between tertiles of FSH levels were compared using adjusted cox regression *** adverse cardiovascular events(MACE)were similarly assessed using hospital admission diagnostic codes.A total of 492 patients were included,with a median follow-up of 13.1(interquartile range:8.9–15.9)*** sulfate(DHEA-S)levels,but not other androgens,negatively correlated with FSH levels on linear regression analysis(P=0.03).There was no association between FSH tertile and outcomes of biochemical recurrence,time to castrate-resistant prostate cancer,or time to *** were identified in 50 patients(10.2%),with a mean time to first event of 8.8 *** association with FSH tertile and occurrence of MACE was *** results do not suggest that preoperative FSH levels are significantly associated with oncologic outcomes among prostate cancer patients treated with radical prostatectomy,nor do these levels appear to be predictors of long-term cardiovascular risk.